Co-Authors
This is a "connection" page, showing publications co-authored by Jinoos Yazdany and Pedro Machado.
Connection Strength
2.739
-
Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers. Ann Rheum Dis. 2021 Feb 18.
Score: 0.930
-
Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al. Ann Rheum Dis. 2021 Aug 23.
Score: 0.241
-
Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al. Ann Rheum Dis. 2021 Aug 13.
Score: 0.240
-
Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum et al. Ann Rheum Dis. 2021 May 13.
Score: 0.236
-
Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Mulhearn et al. Ann Rheum Dis. 2021 Mar 01.
Score: 0.233
-
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. Curr Opin Rheumatol. 2021 03 01; 33(2):111-116.
Score: 0.233
-
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatol. 2021 Oct; 3(10):e707-e714.
Score: 0.060
-
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
Score: 0.059
-
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021 03; 73(3):374-380.
Score: 0.058
-
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 07; 80(7):930-942.
Score: 0.058
-
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. Rheumatology (Oxford). 2021 01 05; 60(1):353-358.
Score: 0.058
-
Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases' by Giollo et al. Ann Rheum Dis. 2020 Sep 07.
Score: 0.056
-
COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al. Ann Rheum Dis. 2020 Aug 12.
Score: 0.056
-
Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi et al. Ann Rheum Dis. 2020 Jun 30.
Score: 0.056
-
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 07; 79(7):859-866.
Score: 0.055
-
Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020 10; 79(10):1386-1388.
Score: 0.055
-
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020 May; 2(5):e250-e253.
Score: 0.055